2022_Dec_DDL_Edinburgh_leaderboard

Pulmonary & Nasal Delivery80

Issue No #80 November 7th, 2017

Inside the magazine

THE SCIENCE BEHIND CAPSULE-BASED DRY POWDER INHALATION TECHNOLOGY

THE SCIENCE BEHIND CAPSULE-BASED DRY POWDER INHALATION TECHNOLOGY

Here, Fernando Díez, Justin Kalafat, and Jnanadeva Bhat explain the mechanics behind cDPIs, from the scientific perspective, before looking to the future of cDPIs in the market.

THE LATEST DIGITAL TOOLS REVEAL ACTUAL PATIENT BEHAVIOUR

THE LATEST DIGITAL TOOLS REVEAL ACTUAL PATIENT BEHAVIOUR

Ryan Noble and Tom Lawrie-Fussey discuss the potential of digital innovations to improve understanding of real patient behaviour and consequently increase adherence.

A SIMPLE AFFORDABLE DPI: MEETING THE NEEDS OF EMERGING MARKETS

Dr Anselm Ebert

A SIMPLE AFFORDABLE DPI: MEETING THE NEEDS OF EMERGING MARKETS

Anselm Ebert, João Ventura Fernandes, Ameet Sule and Sunita Sule discuss the rising need for respiratory medication in the developing world. They go on to highlight the novel challenges presented by these new markets and explain how a new DPI, PowdAir Plus™, meets those challenges, offering a solution to the increase in chronic respiratory conditions across the globe.

ADDRESSING THE CHALLENGES IN NASAL DEVICE TESTING: EVALUATION OF PUMP PERFORMANCE

Proveris Scientific

ADDRESSING THE CHALLENGES IN NASAL DEVICE TESTING: EVALUATION OF PUMP PERFORMANCE

Heli Chauhan details the myriad challenges facing the OINDP market, with a particular emphasis on nasal spray devices, when it comes to testing products on a mass-production scale, such as a lack of adequate testing equipment and the need to capture accurate data consistently. She goes on to offer a solution in the form of Indizo®, Proveris’ automated nasal spray testing apparatus.

AN OVERVIEW OF DRY POWDER INHALATION FOR SYSTEMIC DRUG DELIVERY

AN OVERVIEW OF DRY POWDER INHALATION FOR SYSTEMIC DRUG DELIVERY

Brian Jones and Susana Ecenarro Probst discuss the growing interest in using inhaled APIs to treat systemic conditions. Furthermore, they review some of the methods used to engineer molecules to be suitable for DPI capsules and look to the possibility of administering biomolecules via the pulmonary route.

THE DEVELOPMENT PATH TO BIOEQUIVALENCE FOR A NASAL SPRAY

THE DEVELOPMENT PATH TO BIOEQUIVALENCE FOR A NASAL SPRAY

Pascale Farjas, Alain Regard, and Céline Petitcolas discuss the steps taken when designing a nasal spray device for the growing bioequivalence market and the key competencies, including experience with regulations and regulatory agencies in numerous geographic regions, that Nemera can offer throughout the process.

DEVELOPING EFFECTIVE TRAINING DEVICES FOR THE PULMONARY HEALTHCARE MARKET

DEVELOPING EFFECTIVE TRAINING DEVICES FOR THE PULMONARY HEALTHCARE MARKET

Pulmonary drug delivery is an effective route of pharmaceutical administration but research has shown that a large majority of patients fail to use their devices properly, training devices can help address this problem. Joe Reynolds looks at the design challenges that need to be addressed as well as some of the latest features that can be incorporated to develop optimal training devices for patients.

A NOVEL POWDER FILLING TECHNOLOGY TO REDUCE DEVELOPMENT COSTS & TIMELINES

Simon Strothers

A NOVEL POWDER FILLING TECHNOLOGY TO REDUCE DEVELOPMENT COSTS & TIMELINES

Simon Strothers and Dave Seaward discuss the evolution of filling technology in the inhaled world, including a new technology and approach to filling which offers significant advantages over conventional filling systems.

KEY CONSIDERATIONS FOR NON-CLINICAL SAFETY ASSESSMENT OF INHALED BIOPHARMACEUTICALS

KEY CONSIDERATIONS FOR NON-CLINICAL SAFETY ASSESSMENT OF INHALED BIOPHARMACEUTICALS

Simon Moore, Kirsty Haprer and Sylwia Marshall highlight some of the key considerations for the development of inhaled biopharmaceuticals, including non-clinical safety assessment.

Top